Search | Clinical Trials Finder

Conditions: Sunscreening Agents
Interventions: Sunscreen Sport Lotion (BAY987516), Untreated Skin; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Arteriovenous Malformations (Extracranial)
Interventions: Cobimetinib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 2 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab emtansine [Kadcyla]; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more

Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Inlexisertib, Trametinib, Binimetinib, Sotorasib; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Boston, Massachusetts • St Louis, Missouri • New Brunswick, New Jersey + 7 more

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Hepatitis C
Interventions: ABT-072; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Smoking, Tobacco Use
Interventions: Salt Base Nicotine, Free Base Nicotine; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: End Stage Renal Disease
Interventions: Lanthanum carbonate Granule Formulation, Lanthanum carbonate Chewable Tablets (Fosrenol); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers
Interventions: Lenvatinib 10 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Leishmaniasis
Interventions: GLA-SE, LEISH-F3, MPL-SE, SE; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Major Depressive Disorder
Interventions: Amphetamine/dextroamphetamine, Placebo, Well-being therapy; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
Interventions: Tacrolimus, Early Tacrolimus Taper Strategy; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Kidney Diseases
Interventions: DM199; Drug
Lead sponsor: DiaMedica Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Mesa, Arizona • Granada Hills, California • Los Angeles, California + 11 more

Conditions: Influenza
Interventions: Investigational H7N1 vaccine GSK2789869A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 363 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Hollywood, Florida • Meridian, Idaho • Lenexa, Kansas + 2 more

Conditions: Overweight, Metabolic Syndrome X
Interventions: Placebo, Cr-400, Cr-800, PE-500, PE-1000; Dietary Supplement
Lead sponsor: Kerry Group P.L.C; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Cataract
Interventions: TriMoxiVanc, Moxifloxacin HCl 0.5%, Ilevro, Prednisolone acetate 1%; Drug
Lead sponsor: Carolina Eyecare Physicians, LLC; Other
Eligibility: 50 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Bloomington, Minnesota • Stillwater, Minnesota • Garden City, New York + 1 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride, Leucovorin, Leucovorin Calcium, Liposomal Irinotecan, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 70 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 760
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 501 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Newton, Kansas • Syracuse, New York • Ellensburg, Washington

Conditions: Alzheimer's Disease
Interventions: Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 1,467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Epilepsy
Interventions: nasal Midazolam; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: Semaglutide J, Semaglutide C; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Cypress, California • Kansas City, Kansas

Conditions: Disorder Related to Renal Transplantation
Interventions: Thymoglobulin, Belatacept, Sirolimus, Tacrolimus, Mycophenolate Mofetil (MMF); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more

Conditions: Solid Tumors
Interventions: Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more

Search by objective public record fields.

Human Phototoxicity Test

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

Salt-Based E-cigarette

Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

Stimulant Enhancement of Well-Being Therapy for Depression

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs

Dropless vs. Standard Drops Contralateral Eye Study

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Pharmacodynamics of Nasal and Buccal Midazolam Using EEG

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors